Comments on guideline of diagnostic approach to pauci- or asymptomatic hyperCKemia and the related advances

LI Jianping

doi:10.12022/jnnr.2016-0006

PDF(1613 KB)

Journal of Neurology and Neurorehabilitation ›› 2016, Vol. 12 ›› Issue (2) : 64-70. DOI: 10.12022/jnnr.2016-0006

Comments on Guideline

Comments on guideline of diagnostic approach to pauci- or asymptomatic hyperCKemia and the related advances

LI Jianping

Author information +

History +

Abstract

The evidence-based guideline of diagnostic approach to pauci- or asymptomatic hyperCKemia developed and released by European Federation of Neurological Societies (EFNS) has provided the definition, clinical manifestation, diagnostic procedure and prognosis of this disease. Pauci- or asymptomatic hyperCKemia is defined as a condition that creatine kinase (CK) value beyond 1.5 times the upper limit of normal with no muscular signs. For the etiology searching, collection of the related family history is essential and the non-neuromuscular conditions that might contribute to hyperCKemia are needed to be excluded before further investigation. A muscle biopsy is preferred if one or more of the following are present: the serum CK value is ≥3 times the normal, the electromyogram suggests myopathic condition, the patient is < 25 years of age or there is a clue of exercise intolerance. The long-term prognosis of pauci- or asymptomatic hyperCKemia is generally quite favorable.

Key words

Creatine kinase / HyperCKemia / European Federation of Neurological Societies / Guideline

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LI Jianping. Comments on guideline of diagnostic approach to pauci- or asymptomatic hyperCKemia and the related advances[J]. Journal of Neurology and Neurorehabilitation. 2016, 12(2): 64-70 https://doi.org/10.12022/jnnr.2016-0006

References

[1] KYRIAKIDES T, ANGELINI C, SCHAEFER J, et al. EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia[J]. Eur J Neurol, 2010, 17(6):767-773.
[2] BREWSTER L M, MAIRUHU G, STURK A, et al. Distribution of creatine kinase in the general population: implications for statin therapy[J]. Am Heart J, 2007, 154(4):655-661.
[3] NARDIN R A, ZARRIN A R, HOROWITZ G L, et al. Effect of newly proposed CK reference limits on neuromuscular disorders[J]. M Muscle Nerve, 2009, 39(4):494-497.
[4] LILLENG H, ABELER K, JOHNSEN S H, et al. Variation of serum creatine kinase (CK) levels and prevalence of persistent hyperCKemia in a Norwegian normal population. The Tromsø Study[J]. Neuromuscul Disord, 2011, 21(7):494-500.
[5] LILLENG H, ABELER K, JOHNSEN S H, et al. Clinical impact of persistent hyperCKemia in a Norwegian general population: A case-control study[J]. Neuromuscul Disord, 2013, 23(1):29-35.
[6] ROWLAND L P. Biochemistry of muscle membranes in Duchenne muscular dystrophy[J]. Muscle Nerve, 1980, 3(1):3-20.
[7] BREWSTER L M, DE VISSER M. Persistent hyperCKemia: fourteen patients studied in retrospect[J]. Acta Neurol Scand, 1988, 77(1):60-63.
[8] AFIFI A K. Idiopathic hyperCKemia revisited[J]. J Child Neurol, 1998, 13(6):251-252.
[9] CAPASSO M, DEANGELIS M V, DIMUZIO A, et al. Familial idiopathic hyper-CK-emia: an underrecognized condition[J]. Muscle Nerve, 2006, 33(6):760-765.
[10] PRELLE A, TANCREDI L, SCIACCO M, et al. Retrospective study of a large population of patients with asymptomatic or minimally symptomatic raised serum creatine kinase levels[J]. J Neurol, 2002, 249(3):305-311.
[11] FERNANDEZ C, DE PAULA A M, FIGARELLA-BRANGER D, et al. Diagnostic evaluation of clinically normal subjects with chronic hyperCKemia[J]. Neurology, 2006, 66(10):1585-1587.
[12] FILOSTO M, TONIN P, VATTEMI G, et al. The role of muscle biopsy in investigating isolated muscle pain[J]. Neurology, 2007, 68(3):181-186.
[13] JOY J L, OH S J. Asymptomatic hyper-CK-emia: an electrophysiologic and histopathologic study[J]. Muscle Nerve, 1989, 12(3):206-209.
[14] D’ADDA E, SCIACCO M, FRUGUGLIETTI M E, et al. Follow-up of a large population of asymptomatic/oligosymptomatic hyperckemic subjects[J]. J Neurol, 2006, 253(11):1399-1403.
[15] REIJNEVELD J C, NOTERMANS N C, LINSSEN W H, et al. Benign prognosis in idiopathic hyper-CK-emia[J]. Muscle Nerve, 2000, 23(4):575-579.
[16] REIJNEVELD J C, GINJAAR I B, FRANKHUIZEN W S, et al. CAV3 gene mutation analysis in patients with idiopathic hyper-CK-emia[J]. Muscle Nerve, 2006, 34(5):656-658.
[17] WEGLINSKI M R, WEDEL D J, ENGEL A G. Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels[J]. Anesth Analg, 1997, 84(5):1038-1041.
[18] MALANDRINI A, ORRICO A, GAUDIANO C, et al. Muscle biopsy and in vitro contracture test in subjects with idiopathic HyperCKemia[J]. Anesthesiology, 2008, 109(4):625-628.